

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: <http://www.elsevier.com/locate/crvasa>

Guidelines

2017 ESC/EACTS Guidelines for the management of valvular heart disease

Summary prepared by the Czech Society of Cardiology[☆]

Kateřina Linhartová^{a,*}, Radka Kočková^b, Hana Línková^c

^a Department of Cardiac Surgery, School of Medicine Hospital Plzeň, Plzeň, Czechia

^b Institute for Clinical and Experimental Medicine, Prague, Czech Republic

^c Cardiocenter, 3rd Medical Faculty, Charles University Prague and University Hospital Royal Vineyards, Prague, Czech Republic

Authors of the original ESC/EAS full text document [1]: Helmut Baumgartner, Volkmar Falk on behalf of The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).

ARTICLE INFO

Article history:

Received 10 October 2017

Accepted 12 October 2017

Available online xxx



ČESKÁ KARDIOLOGICKÁ SPOLEČNOST
THE CZECH SOCIETY OF CARDIOLOGY

[☆] For permissions: please e-mail: guidelines@escardio.org.

* Corresponding author.

E-mail address: linhartkaterina@seznam.cz (K. Linhartova).

Abbreviations: Δ Pm, mean transvalvular pressure gradient; 2D, two-dimensional; 3D, three-dimensional; ABC, age, biomarkers, clinical history; ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; AVA, aortic valve area; BAV, balloon aortic valvuloplasty; BNP, B-type natriuretic peptide; BSA, body surface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CI, contra-indication(s); CMR, cardiovascular magnetic resonance; CPG, Committee for Practice Guidelines cardiac resynchronization therapy; CT, computed tomography; EACTS, European Association for Cardio-Thoracic Surgery; ECG, electrocardiogram; EDV, end-diastolic velocity; EROA, effective regurgitant orifice area; ESC, European Society of Cardiology; EuroSCORE, European System for Cardiac Operative Risk Evaluation; INR, international normalized ratio; IV, intravenous; LA, left atrium/left atrial; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVOT, left ventricular outflow tract; MSCT, multislice computed tomography; NOAC, non-vitamin K antagonist oral anticoagulant.

<https://doi.org/10.1016/j.crvasa.2017.10.006>

0010-8650/© 2017 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights reserved.

Contents

1. Preamble	000
2. General comments	000
2.1. Echocardiography	000
2.2. Other non-invasive investigations	000
2.3. Invasive investigations	000
2.4. Concept of the Heart Team and heart valve centres	000
2.5. Management of associated conditions	000
3. Aortic regurgitation	000
3.1. Evaluation	000
3.2. Indications for intervention	000
3.3. Medical therapy	000
3.4. Serial testing	000
4. Aortic stenosis	000
4.1. Evaluation	000
4.2. Indications for interventions (see Table 3 and Fig. 3)	000
4.3. Medical therapy	000
4.4. Serial testing	000
4.5. Special patient populations	000
5. Mitral regurgitation (MR)	000
5.1. Primary MR	000
5.1.1. Evaluation	000
5.1.2. Indications for intervention	000
5.1.3. Medical therapy	000
5.1.4. Serial testing	000
5.2. Secondary MR	000
5.2.1. Evaluation	000
5.2.2. Indications for intervention (see in table)	000
5.2.3. Medical therapy	000
6. Mitral stenosis (MS)	000
6.1. Evaluation	000
6.2. Indication for intervention	000
6.3. Medical therapy	000
7. Tricuspid regurgitation	000
7.1. Evaluation	000
7.2. Indications for intervention	000
8. Tricuspid stenosis	000
8.1. Evaluation	000
8.2. Indications for intervention	000
9. Combined and multiple-valve diseases	000
10. Prosthetic valves	000
10.1. Choice of prosthetic valve	000
10.2. Management after valve intervention	000
11. Management during non-cardiac surgery	000
11.1. Preoperative evaluation	000
11.2. Specific valve lesions	000
12. Management during pregnancy	000
12.1. Native valve disease	000
12.2. Prosthetic valves	000
13. To do and not to do messages from the Guidelines	000
14. What is new in the 2017 Valvular Heart Disease Guidelines?	000

Download English Version:

<https://daneshyari.com/en/article/8604846>

Download Persian Version:

<https://daneshyari.com/article/8604846>

[Daneshyari.com](https://daneshyari.com)